JNJ-6143

Start here

Synthesis

Johnson & Johnson has acquired Halda Therapeutics, a biotech built on its RIPTAC (regulated induced proximity targeting chimera) platform, for $3.05 billion. The deal follows Phase I data presented October 25 in an oral session at ESMO 2026 for the oral small molecule JNJ-6143 in advanced prostate cancer, which showed an objective response rate of 75%. The molecule, formerly HLD-0915, is described by Halda as the first RIPTAC to enter clinical study. The acquisition gives J&J full control of the RIPTAC platform and its lead clinical asset, adding a differentiated modality to its prostate cancer pipeline. Further clinical development of JNJ-6143 beyond the Phase I stage, and whether additional RIPTAC molecules from the platform advance, remain open questions.

Written by a model from the reports · updated 1 day ago

Latest developmentOct 27 01:37

Johnson & Johnson has completed the $3.05 billion acquisition of Halda Therapeutics, whose lead RIPTAC molecule JNJ-6143 showed a 75% ORR in Phase I.

Coverage timeline

Follow the coverage to see the different angles.

Oct 27

01:37
x.com
Benjamin Garmezy, MD, on JNJ-6143, a first-in-class oral AR-targeted RIPTAC™, at the optimal dose in metastatic prostate cancer, including high-risk molecular features. #ESMO26

Oct 25

Oct 24

Oct 23

22:34
x.com
🚨⭐🔵 #ESMO26 Novel AR targeted therapies in mCRPC

Heat trend for this story

Heat now 19·Peak in the comparable set 105 (Oct 25 04:00)·Change over 24h in the comparable set -32%·Participants now 15

Participants counted15

Heat over time

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.